Cantor Fitzgerald initiated coverage of Tyra Biosciences (TYRA) with an Overweight rating. A constructive stance on Tyra shares is driven by three high-conviction Phase 2 clinical readouts for dabogratinib, a selective small-molecule FGFR3 inhibitor currently in development, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TYRA:
- Tyra Biosciences initiated with an Overweight at Cantor Fitzgerald
- Tyra Biosciences price target raised to $45 from $30 at H.C. Wainwright
- Buy Rating on Tyra Biosciences Driven by Dabogratinib’s Differentiated FGFR3 Profile and Key Near-Term Phase II Catalyst
- Tyra Biosciences Advances TYRA-300 Bladder Cancer Trial: What Investors Should Watch
- Tyra Biosciences price target raised to $53 from $37 at Wedbush